US Stock MarketDetailed Quotes
PROK ProKidney
- 1.700
- -0.050-2.86%
Trading Oct 15 10:46 ET
214.29MMarket Cap-2833P/E (TTM)
1.740High1.670Low60.44KVolume1.740Open1.750Pre Close102.54KTurnover0.09%Turnover RatioLossP/E (Static)126.05MShares4.44052wk High-0.22P/B121.50MFloat Cap1.12052wk Low--Dividend TTM71.47MShs Float14.190Historical High--Div YieldTTM4.00%Amplitude1.120Historical Low1.696Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
ProKidney Stock Forum
ProKidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S. Believes Phase 3 Regen-016 (Proact 2) Trial Is Not Required for Initial U.S. Registration
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
2 mins ago
ProKidney Corp: Safety Profile Consistent With Prior Studies and Comparable to Kidney Biopsy
ProKidney Corp: Interim Results of Regen-007 Phase 2 Trial Show Stabilization of Kidney Function for 18 Months
ProKidney Corp: Resumed Manufacturing and Both Proact 1 and Proact 2 Phase 3 Trials
NEWS
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
No comment yet